ADMS Adamas Pharmaceuticals Inc

Price (delayed)

$5.045

Market cap

$230.03M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.69

Enterprise value

$276.51M

Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio ...

Highlights
The company's EPS rose by 39% YoY and by 6% QoQ
ADMS's gross profit is up by 31% year-on-year and by 3.9% since the previous quarter
The equity has plunged by 168% from the previous quarter but it has soared by 83% YoY
Adamas Pharmaceuticals's net income has increased by 29% YoY but it has decreased by 3.3% QoQ
ADMS's quick ratio is down by 10% YoY

Key stats

What are the main financial stats of ADMS
Market
Shares outstanding
45.6M
Market cap
$230.03M
Enterprise value
$276.51M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.35
Earnings
Revenue
$82.47M
EBIT
-$41.31M
EBITDA
-$40.64M
Free cash flow
-$51.45M
Per share
EPS
-$1.69
Free cash flow per share
-$1.13
Book value per share
-$0.09
Revenue per share
$1.81
TBVPS
$3.3
Balance sheet
Total assets
$150.64M
Total liabilities
$154.68M
Debt
$135.27M
Equity
-$4.03M
Working capital
$93.83M
Liquidity
Debt to equity
-33.54
Current ratio
5.3
Quick ratio
4.65
Net debt/EBITDA
-1.14
Margins
EBITDA margin
-49.3%
Gross margin
97.6%
Net margin
-66.8%
Operating margin
-51.4%
Efficiency
Return on assets
-38.5%
Return on equity
N/A
Return on invested capital
-25%
Return on capital employed
-32.1%
Return on sales
-50.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADMS stock price

How has the Adamas Pharmaceuticals stock price performed over time
Intraday
-2.61%
1 week
3.38%
1 month
12.61%
1 year
24.88%
YTD
16.51%
QTD
-4.45%

Financial performance

How have Adamas Pharmaceuticals's revenue and profit performed over time
Revenue
$82.47M
Gross profit
$80.47M
Operating income
-$42.42M
Net income
-$55.11M
Gross margin
97.6%
Net margin
-66.8%
The operating margin has grown by 49% YoY
ADMS's net margin is up by 45% YoY
ADMS's operating income is up by 34% year-on-year but it is down by 4.5% since the previous quarter
ADMS's gross profit is up by 31% year-on-year and by 3.9% since the previous quarter

Growth

What is Adamas Pharmaceuticals's growth rate over time

Valuation

What is Adamas Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
2.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.35
The company's EPS rose by 39% YoY and by 6% QoQ
The equity has plunged by 168% from the previous quarter but it has soared by 83% YoY
The stock's price to sales (P/S) is 100% less than its 5-year quarterly average of 888.8 but 36% more than its last 4 quarters average of 2.1
Adamas Pharmaceuticals's revenue has increased by 30% YoY and by 4% QoQ

Efficiency

How efficient is Adamas Pharmaceuticals business performance
The company's return on sales rose by 50% YoY
The return on assets is up by 23% year-on-year
Adamas Pharmaceuticals's return on invested capital has increased by 16% YoY but it has decreased by 12% QoQ

Dividends

What is ADMS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADMS.

Financial health

How did Adamas Pharmaceuticals financials performed over time
ADMS's total assets is 2.6% less than its total liabilities
ADMS's total assets is up by 13% YoY but it is down by 11% from the previous quarter
ADMS's quick ratio is down by 10% YoY
The equity has plunged by 168% from the previous quarter but it has soared by 83% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.